Sanofi's next-generation insulin shows edge over Lantus

June 22, 2013 3:06 PM

10 0

Sanofi's next-generation insulin shows edge over Lantus

PARIS (Reuters) - An improved version of Sanofi's blockbuster insulin Lantus is better than the older drug at controlling blood sugar lows at night, a common side effect in diabetics treated with insulin, according two late-stage tests published on Saturday.

The results for the next-generation treatment, known as U300, could strengthen Sanofi's position as it defends its no. 2 spot in the $43 billion diabetes market from rival drugs.

Also read: Apple tells feds ‘new entrants’ to auto industry should get same testing rights as incumbents

Read more

To category page

Loading...